Moreover, the expression of cytoplasmic RAP1 could serve as a biomarker to screen NSCLC patients for their sensitivity to CP, thus enabling the pre-CP application of chemotherapy agent to the cohort with better expected responses. This evidence concerns the gene TERF2IP and non-small cell lung carcinoma.